Research location
Khodosovka
Kyivska Oblast, Ukraine
Advertisement
Research activity in Khodosovka
Kyivska Oblast, UkraineCureCurrent currently publishes aggregate city-level research activity for this location: 7 trials and 7 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Khodosovka
7 linked trials · page 1 of 1Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)NCT04956692 · 2021-08-05 · 1 site observation
COMPLETED
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPCNCT04821622 · 2021-05-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced MalignanciesNCT04181788 · 2020-03-18 · 1 site observation
COMPLETED
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)NCT03976323 · 2019-06-28 · 1 site observation
COMPLETED
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)NCT03976362 · 2019-06-28 · 1 site observation
COMPLETED
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)NCT03924869 · 2019-06-25 · 1 site observation
TERMINATED
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)NCT03615326 · 2018-10-05 · 1 site observation
COMPLETED
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.